
Abstract Obesity is a global health challenge that is strongly associated with type 2 diabetes and cardiovascular disease. Incretin receptor agonists produce substantial weight loss, whereas structured exercise provides distinct benefits for cardiorespiratory fitness, metabolic health, and body composition preservation. This systematic review synthesized clinical studies of GLP-1 receptor agonists, dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists, structured exercise, and combined strategies in adults with obesity, overweight, or type 2 diabetes. Three databases were searched in accordance with PRISMA 2020, and 31 studies comprising approximately 10,044 participants were included. Pharmacotherapy trials consistently favored incretin-based treatment over placebo or usual care for the body weight and glycemic outcomes. However, direct drug-plus-exercise versus drug-alone comparisons were few, exercise prescriptions and background lifestyle programs were heterogeneous, and several studies evaluated counseling rather than supervised training. Only a subset of studies reported means and standard deviations in a form suitable for pooling, so the quantitative synthesis shown in the main figures is restricted to descriptive within-group changes from baseline to postintervention and does not estimate between-group treatment effects. Studies whose randomized contrast was dietary education or general physical activity advice were classified as background lifestyle care rather than structured exercise, and every study is classified individually so that no statement about supervised training rests on them. Direct between-group comparisons were performed on postintervention values for every outcome, and they are reported in the Supporting Information. No outcome differed significantly between groups in the studies that combined pharmacotherapy with an exercise or lifestyle cointervention, whereas body weight and body mass index favored the drug in the pharmacotherapy-only studies, as expected from established efficacy. Direct drug-plus-exercise versus drug-alone evidence was therefore summarized narratively, and heterogeneity was substantial for the glycemic outcomes. Limited evidence suggests a possible complementary benefit of combining pharmacotherapy with structured exercise, particularly for fitness, body composition, and weight maintenance, but the certainty and generalizability of this evidence remain limited. The evidence base consists of short trials conducted almost entirely in high-income settings, with limited geographic, ethnic, and socioeconomic diversity and little reporting of adherence or sex-stratified effects; therefore, it cannot establish how combined therapy would perform across diverse health systems and populations. These findings support individualized multidisciplinary obesity care while highlighting the need for adequately powered, factorial trials.
Abstract Neuroinflammation plays a key role in the progression of various neurodegenerative diseases, including Alzheimer’s disease (AD). Sitagliptin, a widely used antidiabetic drug, has shown neuroprotective and anti-inflammatory effects, including the reduction of tumor necrosis factor-α (TNF-α) expression. This study aimed to design, develop, and evaluate lipid-based nanoparticle formulations of sitagliptin for enhanced brain delivery and treatment of neuroinflammation. Sitagliptin-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) were prepared using homogenization and ultrasonication, with formulation parameters optimized through experimental design. The optimized nanoparticles were characterized for physicochemical properties, drug release behavior, cytotoxicity, and in vivo efficacy. Both formulations successfully encapsulated sitagliptin and exhibited mean particle sizes of approximately 50 nm. Drug release studies demonstrated a slower release profile for SLNs compared with NLCs. Cytotoxicity assessment using HepG2 cells indicated that both formulations were safe at low concentrations, while NLCs showed a more favorable safety profile at higher concentrations. In a mouse model of neuroinflammation, both nanoparticle systems improved behavioral outcomes and significantly reduced TNF-α expression in brain tissue, indicating enhanced brain delivery and anti-inflammatory activity. Overall, both SLNs and NLCs effectively attenuated neuroinflammation; however, NLCs demonstrated superior efficacy and safety, highlighting their potential as a promising delivery platform for sitagliptin in the treatment of AD-associated neuroinflammation.
Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by uncontrolled proliferation of immature myeloid cells and remains associated with poor clinical outcomes despite recent therapeutic advances. The introduction of the BCL-2 inhibitor venetoclax has significantly improved response rates, particularly in combination with hypomethylating agents, yet primary and acquired resistance frequently limits durable remission. Mechanisms underlying resistance include apoptotic rewiring; overexpression of MCL-1 and BCL-XL; activation of PI3K/AKT/mTOR, MAPK, NF-κB, and STAT3 signaling; metabolic reprogramming; leukemia stem-cell persistence; epigenetic dysregulation; and protective interactions within the bone marrow microenvironment. Natural products represent a promising source of multitarget therapeutic agents capable of modulating diverse oncogenic networks involved in AML progression and drug resistance. This review comprehensively summarizes the antileukemic potential of phytochemicals including curcumin, parthenolide, resveratrol, quercetin, honokiol, matrine, wogonin, withanolides, homoharringtonine, avocatin B, ajoene, and apigenin. Particular emphasis is placed on their ability to induce apoptosis, eradicate leukemia stem cells, suppress metabolic adaptations, trigger ferroptosis, reverse epigenetic abnormalities, and remodel the tumor microenvironment. We critically evaluate the evidence supporting these mechanisms and discuss translational opportunities, combination strategies, formulation advances, and current challenges related to bioavailability, pharmacokinetics, and biomarker-guided patient selection. We propose that natural products, when integrated into precision medicine frameworks and advanced delivery systems, offer substantial potential as adjunctive therapies for overcoming venetoclax resistance. However, successful clinical translation requires rigorous pharmacokinetic optimization, biomarker-guided patient stratification, and well-designed clinical trials.
Chronic diabetic wounds are characterized by persistent inflammation, oxidative stress, and impaired neovascularization. To address this pathological problem, we developed a bioactive composite hydrogel by encapsulating the platelet-rich plasma derived from deer blood, named ApiRegenin; the hydrogel network was formed by a photoactivated cross-linking of gelatin methacryloyl (GelMA) and hydrophilic carboxymethyl chitosan (CMCS). The optimized formulation of 5% GelMA, 2% CMCS, and 20% ApiRegenin (Api–Gel) exhibited an interconnected porous microstructure, shear-thinning behavior, and rapid self-healing, and, more importantly, an optimized regenerative activity in skin wounds. In diabetic (db/db) mice, Api–Gel significantly accelerated wound closure, achieving complete re-epithelialization and appendage regeneration by day 14. Histological and immunofluorescence analyses revealed that Api–Gel promoted CD31/VEGF-mediated neovascularization, resolved local hypoxia (reducing HIF-1α), and drove macrophage polarization from the M1 to M2 phenotype. Transcriptomics identified that Api–Gel upregulated epidermal development and matrix deposition while suppressing inflammatory genes. Mechanistically, Api–Gel activated the endogenous Nrf2/HO-1 signaling pathway, initiating antioxidant defenses and scavenging intracellular reactive oxygen species under inflammatory stress. This multitargeted platform coordinates immunomodulation, angiogenesis, and antioxidant defense, offering promising translational potential for diabetic wound therapy.
Abstract Glioblastoma (GBM), one of the most aggressive and lethal primary brain tumors, remains a major challenge in neuro-oncology. The Wingless/Int-1 (Wnt)/β-catenin pathway has emerged as a potential therapeutic target for gliomas. However, owing to the lack of small-molecule inhibitors targeting B-cell lymphoma 9 (BCL9), a coactivator of β-catenin, the therapeutic potential of BCL9 in GBM has not been pharmacologically validated. Here, we report a novel small-molecule inhibitor of the BCL9/β-catenin interaction, designated ZD37-28R. Molecular docking suggested that ZD37-28R binds to β-catenin with high affinity. In vitro, ZD37-28R disrupted the interaction between BCL9 and β-catenin, markedly inhibited β-catenin-dependent transcriptional activity, and reduced the proliferation and migration of U87-MG and U251 GBM cells. Oil Red O staining and fluorescence-activated cell sorting further showed that ZD37-28R decreased lipid accumulation and lipid reactive oxygen species in GBM cells. These effects were associated with reduced expression of sterol regulatory element-binding protein 1 (SREBP1), a key regulator of lipid metabolism, thereby further impairing the viability and migration of glioma cells. In a subcutaneous glioma model, ZD37-28R exhibited robust antitumor activity with low toxicity. In an orthotopic glioma model, ZD37-28R showed antitumor efficacy and enhanced the effect of temozolomide (TMZ), as evaluated by magnetic resonance imaging. Taken together, our study identifies ZD37-28R as a novel BCL9/β-catenin inhibitor and suggests that it may represent a promising lead compound for GBM treatment, particularly in combination with TMZ.